<DOC>
	<DOCNO>NCT01180699</DOCNO>
	<brief_summary>Influenza virus important cause morbidity transplant population lead viral bacterial pneumonia contribute development rejection . Although annual influenza vaccine recommend transplant patient , study show single intramuscular dose poor immunogenicity . There study define effect intradermal dos population . We plan study immunogenicity two different administration route influenza vaccine 200 solid organ transplant patient 2010-2011 season . Patients randomize receive influenza vaccine either intradermally intramuscularly . We hypothesize patient receive intradermal influenza vaccine significantly reach high response vaccine . This study advance research prevention serious viral infection transplant recipient . Results study potential directly improve patient care . If use intradermal influenza vaccine successful , strategy may lead significant reduction burden disease , hospitalization , long-term morbidity .</brief_summary>
	<brief_title>Intradermal Versus Intramuscular Trivalent Influenza Vaccine Adult Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 18 ≤ 59 , Greater 3 month posttransplant , Any solid organ transplant ( kidney , liver , heart , lung , pancreas , intestinal combination aforementioned organ ) Has already receive influenza vaccination 20102011 season ; Egg allergy , Previous lifethreatening reaction influenza vaccine ( i.e . Guillain Barre Syndrome ) , Ongoing therapy rejection , Febrile illness past two week , Unable provide inform consent , Unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>adult solid organ transplant patient</keyword>
</DOC>